ReviewMedGenMed : Medscape general medicine2005
Omalizumab: a monoclonal anti-IgE antibody.
Review in MedGenMed : Medscape general medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 84 citations in OpenAlex.
- Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles.The Journal of allergy and clinical immunology · 2019Trial
- Review
- Review
- The relationship between Fc epsilon receptor-1α and β (Postepy dermatologii i alergologii · 2024Article
- A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate-to-severe asthma.Clinical and translational allergy · 2023Article
- Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes.Journal of clinical medicine · 2023Review
- Clinical trials of antibody drugs in the treatments of atopic dermatitis.Frontiers in medicine · 2023Review
- Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Therapeutical Targets in Allergic Inflammation.Biomedicines · 2022Review
- Comparison between clinical trials and real-world evidence studies on biologics for severe asthma.The Journal of international medical research · 2022Review
- Review
- Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms.Allergy, asthma & immunology research · 2022Review
- Severe asthma in children: An official statement from Saudi Pediatric Pulmonology Association.Saudi medical journal · 2022Article
- Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy.Frontiers in immunology · 2022Article
- Feasibility of plant-expression system for production of recombinant anti-human IgE: An alternative production platform for therapeutic monoclonal antibodies.Frontiers in plant science · 2022Article
- Pediatric usage of Omalizumab: A promising one.The World Allergy Organization journal · 2021Review
- Cryptococcosis in the Vocal Cords, Trachea, and Bronchi.Internal medicine (Tokyo, Japan) · 2021Article
- Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021Article
- Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.Scientific reports · 2020Article
- Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab.
methodsMEDLINE, In-Process & Other Non-Indexed Citations, and EMBASE Drugs & Pharmacology were searched using olizumab, omalizumab, E25, rhuMAb-E25, and anti-IgE. Combinations of rhinitis, asthma, and IgE captured information on disease pathophysiology.
resultsOmalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin (Ig)E. Bound IgE is not available for basophil binding, degranulation is attenuated, and allergic symptoms are reduced. In asthma trials, omalizumab reduced inhaled corticosteroid and rescue medication requirements and improved asthma control and asthma quality of life in moderate to severe allergic asthmatics with disease poorly controlled by inhaled corticosteroids. In trials of patients with poorly controlled moderate to severe seasonal allergic rhinitis (SAR), omalizumab reduced the severity of exacerbations and rescue medication use, and improved rhinitis-related quality of life. Benefits were also observed in trials utilizing combinations of immunotherapy and omalizumab for SAR and in trials of perennial allergic rhinitis (PAR). Omalizumab has been well tolerated. Although malignant neoplasms have been observed in treated patients, they were likely not related to omalizumab therapy.
conclusionsOmalizumab has demonstrated efficacy in children, adults, and adolescents with uncontrolled moderate to severe allergic asthma and allergic rhinitis. Long-term safety beyond 52 weeks needs continued evaluation.
Indexed as
Identifiers
16369332PMC1681435W2406400390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.